Serious question: What does the future hold for Astellas?

Quote























Technically, the Sept 2022 date is the earliest that Myrbetriq could face generic competition. There is a good chance that the real date will be sometime in 2023 (or later). The law isn't black and white, and the courts will ultimately decide when a generic manufacturer can start selling Myrbetriq.
 



anonymous said:
We are suffering from PISS POOR SALES LEADERSHIP, and a FAILED R&D DEPARTMENT.

We also have Northbrook that is only worried about what the next promotion is.

Astellas has how many products? PISS POOR LEADERSHIP! We have Pfizer at all levels of leadership implementing the same failed initiatives that got them here in the first place. VP of Sales, Area VP, Directors, and Managers mostly from Pfizer.

They let the Texas Managers win multiple summit clubs illegitimately over a decade all carefully orchestrated by the people who were fired by compliance and who left for greener pastures. Some are still roaming the halls. You know who you are. We must clean this company of the filthy cheaters.
Click to expand...
Very true. Great place for reps to voice their opinion. Wish other parts of the company could too. Medical, specifically medical communications is led by a couple of selfish and incompetent non-leaders. They are the most superficial, position grabbing, self promoting liars. Fake exterior evil insides.
 













Write your reply...
Top Bottom
Back
Quote